Dexcom, Inc., a leader in glucose biosensing technology, on Tuesday announced the launch of its proprietary Generative AI platform, becoming the first continuous glucose monitor (CGM) manufacturer to integrate GenAI into its technology . The new Dexcom GenAI platform analyzes individual health data patterns to identify connections between lifestyle choices and glucose levels, providing actionable insights for improved metabolic health .